tiprankstipranks

HUTCHMED Hosts ITP Treatment Webcast and Progresses Drug Trial

HUTCHMED Hosts ITP Treatment Webcast and Progresses Drug Trial

HUTCHMED (China) Limited (HK:0013) has released an update.

HUTCHMED (China) Limited will be hosting an informative webcast featuring an expert on immune thrombocytopenia (ITP) to discuss the treatment landscape of the condition. The company has also announced positive Phase III trial results for its drug sovleplenib, aimed at treating ITP, and has filed a New Drug Application in China. HUTCHMED is a biopharmaceutical company focused on developing targeted therapies and immunotherapies, with a growing global presence and a robust pipeline of drug candidates.

For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App